BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 9933655)

  • 1. Can tumour marker assays be a guide in the prescription of bone scan for breast and lung cancers?
    Buffaz PD; Gauchez AS; Caravel JP; Vuillez JP; Cura C; Agnius-Delord C; Fagret D
    Eur J Nucl Med; 1999 Jan; 26(1):8-11. PubMed ID: 9933655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
    Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
    Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumour marker CA15-3: possible uses in the routine management of breast cancer.
    Tomlinson IP; Whyman A; Barrett JA; Kremer JK
    Eur J Cancer; 1995 Jun; 31A(6):899-902. PubMed ID: 7646918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between bone scintigraphy and tumor markers in patients with breast cancer.
    Yildiz M; Oral B; Bozkurt M; Cobaner A
    Ann Nucl Med; 2004 Sep; 18(6):501-5. PubMed ID: 15515750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of tumour markers in predicting skeletal metastases in breast cancer patients with equivocal bone scintigraphy.
    Nicolini A; Ferrari P; Sagripanti A; Carpi A
    Br J Cancer; 1999 Mar; 79(9-10):1443-7. PubMed ID: 10188888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of bone metastases in breast cancer patients in the PET/CT era: Do we still need the bone scan?
    Caglar M; Kupik O; Karabulut E; Høilund-Carlsen PF
    Rev Esp Med Nucl Imagen Mol; 2016; 35(1):3-11. PubMed ID: 26514321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of malignancy in pulmonary lesions: FDG dual-head coincidence gamma camera imaging in association with serum tumor marker measurement.
    Bousson V; Moretti JL; Weinmann P; Safi N; Tamgac F; Groiselle C; de Beco V; Hillali Y; Valeyre D; Breau JL
    J Nucl Med; 2000 Nov; 41(11):1801-7. PubMed ID: 11079486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CA 15-3 and bone scintigraphy in the follow-up of breast cancer.
    Younsi N; Montravers F; Philippe C; Seddiki M; Uzan S; Izrael V; Talbot JN
    Int J Biol Markers; 1997; 12(4):154-7. PubMed ID: 9582604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters.
    Chybowski FM; Keller JJ; Bergstralh EJ; Oesterling JE
    J Urol; 1991 Feb; 145(2):313-8. PubMed ID: 1703240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of bone scintigraphy with serum tumor markers of CA 15-3 and carcinoembryonic antigen in patients with breast carcinoma.
    Gedik GK; Kiratli PO; Tascioglu B; Aras T
    Saudi Med J; 2006 Mar; 27(3):317-22. PubMed ID: 16532090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
    Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P
    BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The status of nuclear medicine techniques in the diagnosis of bone metastases in breast cancer.
    Makaiová I; Kausitz J; Hupka S; Michaliková B; Vivodová M; Bohunický L
    Czech Med; 1989; 12(1):34-9. PubMed ID: 2498049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serial tumour markers serum carcinoembryonic antigen and cancer antigen 15-3 assays in detecting symptomatic metastasis in breast cancer patients.
    Bahrami A; Mortazavizadeh MR; Yazdi MF; Chamani M
    East Mediterr Health J; 2012 Oct; 18(10):1055-9. PubMed ID: 23301361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of a serum tumour marker panel in the post-operative follow-up of breast cancer patients with equivocal conventional radiological examinations.
    Nicolini A; Carpi A; Ferrari P; Pieri L
    Tumour Biol; 2003; 24(6):275-80. PubMed ID: 15004486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone scintigraphy and the added value of SPECT (single photon emission tomography) in detecting skeletal lesions.
    Savelli G; Maffioli L; Maccauro M; De Deckere E; Bombardieri E
    Q J Nucl Med; 2001 Mar; 45(1):27-37. PubMed ID: 11456373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is parathyroid hormone-related protein a sensitive serum marker in advanced breast cancer?
    Pyke CM; Menezes G; Purdie DM; Johnson S; Cowley D
    Aust N Z J Surg; 1997 May; 67(5):256-9. PubMed ID: 9152154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The semiquantitative bone scintigraphy index correlates with serum tartrate-resistant acid phosphatase activity in breast cancer patients with bone metastasis.
    Tsai SH; Chen CY; Ku CH; Janckila AJ; Yam LT; Yu JC; Chuang KW; Chao TY
    Mayo Clin Proc; 2007 Aug; 82(8):917-26. PubMed ID: 17673059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Procollagen-I, collagen telopeptide I, CEA, CA 15-3 as compared to bone scintigraphy in patients with breast cancer].
    Zissimopoulos A; Petrakis G; Stellos K; Baziotis N
    Hell J Nucl Med; 2006; 9(1):60-4. PubMed ID: 16617400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic value of chest radiography, computed tomography and tumour markers in the differentiation of malignant from benign solitary pulmonary lesions.
    Seemann MD; Seemann O; Dienemann H; Schalhorn A; Prime G; Fink U
    Eur J Med Res; 1999 Aug; 4(8):313-27. PubMed ID: 10471543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum CYFRA 21-1 is one of the most reliable tumor markers for breast carcinoma.
    Nakata B; Ogawa Y; Ishikawa T; Ikeda K; Kato Y; Nishino H; Hirakawa K
    Cancer; 2000 Sep; 89(6):1285-90. PubMed ID: 11002224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.